On October 2, 2018 BioInvent International AB (OMXS: BINV) reported that the company will present two posters together with its transgender for a new checkpoint blocking antibody optimized for slow elimination and its targeted oncolytic virus vector at Society for the Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)s (SITC) (Free SITC Whitepaper) annual meeting that will be held November 7-11 in Washington DC (USA) (Press release, BioInvent, OCT 2, 2018, View Source [SID1234529707]). The anti-CTLA-4 antibody encoding oncolytic virus product candidate is developed for tumor localized cancer immunotherapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Generation and characterization of a CTLA-4 antibody with improved Fc γ R -dependent Treg deletion of tumor microenvironment-targeted oncolytic virotherapy of cancer
Author: Monika Semmrich, Jean-Baptiste Marchand, Petra Holmkvist, Linda Mårtensson, Ulla-Carin Tornberg, Laetitia Fend, Mathilda Kovacek, Ulla-Carin Tornberg, Ingrid Teige, Andre McAllister, Eric Quéméneur, Björn Frendéus.
Poster number: P602
Antibody-armed oncolytic vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Author: Jean-Baptiste Marchand, Monika Semmrich, Laetitia Fend, Ulla-Carin Tornberg, Nathalie Silvestre, Björn Frendéus, Eric Quéméneur
Poster number: P615
The posters will be shown on Friday and Saturday, November 9-10 in the poster (hall E).
Björn Frendéus, BioInvents Chief Scientific Officer, said: "We are pleased to announce a potentially safe and more effective strategy for combining anti-CTLA 4 and anti-PD-1 / PDL1 checkpoint inhibition in oncolytic viral therapy. By building on the extensive clinical validation of checkpoint blockers, onkoviral tumor localized administration of our monoclonal antibody optimized for slow elimination potential has improved the therapeutic window for CLTA-4 targeted checkpoint intervention, enabling a better tolerated and more effective combination therapy with approved antibodies directed against the PD-1 / PD-L1 axis. "